Loading…
Reported covered position: Leg. Assistant to Sen. Wyden (2013-2014)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation, 21st Century Cures Initiative, Innovation for Healthier Americans Initiative, Prescription Drug Pricing, Abuse-Deterrent Prescription Drug Formulations, H.R. 406 Combination Drug Development Incentive Act, H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act, H.R. 1576 Generic Complex Drugs Safety and Effectiveness for Patients Act
Combination Drug Development Incentive Act of 2015
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASSOCIATION FOR ACCESSIBLE MEDICINES via ASSOCIATION FOR ACCESSIBLE MEDICINES
2015 · first_quarter · Q1
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation, 21st Century Cures Initiative, Innovation for Healthier Americans Initiative, Prescription Drug Pricing, Abuse-Deterrent Prescription Drug Formulations, H.R. 406 Combination Drug Development Incentive Act, H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act, H.R. 1576 Generic Complex Drugs Safety and Effectiveness for Patients Act
Source: Senate LDA
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation, 21st Century Cures Initiative, Innovation for Healthier Americans Initiative, Prescription Drug Pricing, Abuse-Deterrent Prescription Drug Formulations, H.R. 406 Combination Drug Development Incentive Act, H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act, H.R. 1576 Generic Complex Drugs Safety and Effectiveness for Patients Act
Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation, 21st Century Cures Initiative, Innovation for Healthier Americans Initiative, Prescription Drug Pricing, Abuse-Deterrent Prescription Drug Formulations, H.R. 406 Combination Drug Development Incentive Act, H.R. 971 Orphan Product Extensions Now Accelerating Cures and Treatments Act, H.R. 1576 Generic Complex Drugs Safety and Effectiveness for Patients Act
Medicare Drug Savings Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Medicare Part D Program and Generic Drugs, H.R. 1588, Medicare Drug Savings Act of 2013, S. 740, Medicare Drug Savings Act of 2013
Food and Drug Administration Safety Over Sequestration Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Combination Drug Development Incentive Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Combination Drug Development Incentive Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Combination Drug Development Incentive Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
MODDERN Cures Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
MODDERN Cures Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Bipartisan Congressional Trade Priorities Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Trans Pacific Partnership, H.R. 3830 the Bipartisan Congressional Trade Priorities Act, S. 1900 the Bipartisan Congressional Trade Priorities Act
Generic Drug Pricing Fairness Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Generic Drug Pricing Fairness Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
Stop Tampering of Prescription Pills Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Fair Access for Safe and Timely Generics Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
Fair Access for Safe and Timely Generics Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Medicaid Generic Drug Price Fairness Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Medicare Part D Program and Generic Drugs, H.R. 5748 Medicaid Generic Drug Price Fairness Act, S. 2948 Medicaid Generic Drug Price Fairness Act
FDA User Fee Protection Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Bipartisan Congressional Trade Priorities Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Trans Pacific Partnership, H.R. 3830 the Bipartisan Congressional Trade Priorities Act, S. 1900 the Bipartisan Congressional Trade Priorities Act
Medicaid Generic Drug Price Fairness Act
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Medicare Part D Program and Generic Drugs, H.R. 5748 Medicaid Generic Drug Price Fairness Act, S. 2948 Medicaid Generic Drug Price Fairness Act
Dormant Therapies Act of 2014
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Medicare Drug Savings Act of 2013
Client: ASSOCIATION FOR ACCESSIBLE MEDICINES · Firm: ASSOCIATION FOR ACCESSIBLE MEDICINES
Medicare Part D Program and Generic Drugs, H.R. 1588, Medicare Drug Savings Act of 2013, S. 740, Medicare Drug Savings Act of 2013
Medicare Part D Program and Generic Drugs, Medicare Part D Non-Interference, Prescription Drug Pricing, Low-Income Subsidy in Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via ASSOCIATION FOR ACCESSIBLE MEDICINES
2014 · fourth_quarter · Q4
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, S. 3004 Dormant Therapies Act, Issues Regarding Market Exclusivity, Drug Quality and Security Act Implementation
Medicare Part D Program and Generic Drugs, H.R. 5748 Medicaid Generic Drug Price Fairness Act, S. 2948 Medicaid Generic Drug Price Fairness Act
Trans Pacific Partnership, H.R. 3830 the Bipartisan Congressional Trade Priorities Act, S. 1900 the Bipartisan Congressional Trade Priorities Act
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASSOCIATION FOR ACCESSIBLE MEDICINES via ASSOCIATION FOR ACCESSIBLE MEDICINES
2014 · third_quarter · Q3
Medicare Part D Program and Generic Drugs
Implementation of FDASIA and GDUFA, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation and Mitigation Strategies, Biosimilars Naming, Electronic Labeling for Pharmaceuticals, Generic Drugs Savings, H.R. 5657 Fair Access for Safe and Timely Generics Act, H.R. 3116 MODDERN Cures Act, H.R. 2985 Combination Drug Development Incentive Act, H.R. 4437 Generic Drug Pricing Fairness Act, Issues Regarding Market Exclusivity
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ASSOCIATION FOR ACCESSIBLE MEDICINES via ASSOCIATION FOR ACCESSIBLE MEDICINES
2014 · second_quarter · Q2
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Medicare Part D Program and Generic Drugs, H.R. 1588, Medicare Drug Savings Act of 2013, S. 740, Medicare Drug Savings Act of 2013
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office